Karyopharm Therapeutics (NASDAQ:KPTI) is entering a pivotal year for its oncology pipeline, with the company forecasting a duo of high-stakes clinical trial readouts that could redefine its market position as its current cash runway nears its end.
The Newton, Massachusetts-based biotech expects preliminary full-year 2025 total revenue to reach approximately $145 million, primarily anchored by $115 million in U.S. sales of its flagship multiple myeloma drug, XPOVIO.
While commercial demand remained steady throughout the year, the market’s focus has shifted toward Karyopharm’s late-stage development programs.
The company's top priority for 2026 is the SENTRY trial in myelofibrosis, which completed enrollment of 353 patients in late 2025.
Top-line data for the Phase 3 study, evaluating selinexor in combination with ruxolitinib, is expected in March 2026.
Management believes a positive result could unlock a "multi-billion dollar" opportunity in the front-line myelofibrosis market.
A second major catalyst follows in mid-2026 with data from the XPORT-EC-042 trial in endometrial cancer.
However, despite the clinical momentum, Karyopharm faces a tight financial window.
The company ended 2025 with approximately $64 million in liquidity, a balance bolstered by recent strategic financings but only expected to fund operations into the second quarter of 2026.
This timeline places the company in a high-pressure "binary" position, where its ability to secure further capital likely hinges on the success of the March data readout.